Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 10:15:1472430.
doi: 10.3389/fimmu.2024.1472430. eCollection 2024.

Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC

Affiliations
Review

Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC

Muhammad Naveed Khan et al. Front Immunol. .

Abstract

HBV infection is a key risk factor for the development and progression of hepatocellular carcinoma (HCC), a highly invasive tumor, and is characterized by its persistent immunosuppressive microenvironment. This review provides an in-depth analysis of HBV-related HCC and explores the interactions between neutrophils, natural killer cells, and dendritic cells, examining their roles in regulating tumor-associated macrophages and CD8+ T cells and shaping the tumor microenvironment. Two critical players in the immunosuppressive milieu of HBV-related HCC are CD8+ T cells and tumor-associated macrophages (TAMs). The study explores how TAMs, initially recruited to combat infection, transform, adopting a tumor-promoting phenotype, turning against the body, promoting tumor cell proliferation, suppressing anti-tumor immunity, and assisting in the spread of cancer. Meanwhile, CD8+ T cells, crucial for controlling HBV infection, become dysfunctional and exhausted in response to persistent chronic viral inflammation. The review then dissects how TAMs manipulate this immune response, further depleting CD8+ T cell functions through mechanisms like arginine deprivation and creating hypoxic environments that lead to exhaustion. Finally, it explores the challenges and promising therapeutic avenues that target TAMs and CD8+ T cells, either separately or in combination with antiviral therapy and personalized medicine approaches, offering hope for improved outcomes in HBV-related HCC.

Keywords: CD8+ T cell; HBV-related HCC; TAMs-like macrophage; hepatitis B virus; immunology; pathogenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Shows the intricate interaction among different populations of immune cells in the context of HBV-related HCC. The primary emphasis is tumor-associated macrophages (TAMs) and CD8+ T cells as well as their interactions with other immune cells, such as Neutrophils, Natural killer (NK) cells and Dendritic cells (DCs). The figure is created with BioRender.com.
Figure 2
Figure 2
Shows the development of macrophages in HBV-HCC, showing their diverse origins and the mechanism of M1/M2 polarization, as well as their role in cancer. The figure is created with BioRender.com.
Figure 3
Figure 3
Illustrates the dual nature of CD8+ T cells in the context of HBV-HCC. It is establishing a balance between viral management, anticancer activity, and exhaustion against cancer.
Figure 4
Figure 4
This figure highlights the interplay between TAMs and CD8+ T cells in the TME of HBV-related HCC. TAMs suppress CD8+ T cell function by several mechanisms such as direct and indirect macrophage events, arginine deprivation, and hypoxia.

Similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. . Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. (2022) 161:108–18. doi: 10.1016/j.ejca.2021.11.023 - DOI - PubMed
    1. WHO . Hepatitis B (2023). World Health organization. Available online at: https://wwwwhoint/news-room/fact-sheets/detail/hepatitis-b (Accessed Dec 28 2023).
    1. Sitia G. Towards personalized medicine in chronic HBV patients? Liver Int. (2015) 35:1783–5. doi: 10.1111/liv.12806 - DOI - PubMed
    1. Mason WS, Jilbert AR, Litwin S. Hepatitis B virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver. Viruses. (2021) 13(2):210. doi: 10.3390/v13020210 - DOI - PMC - PubMed

MeSH terms